Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
48
QTTB Quote, Financials, Valuation and Earnings
Last price:
$3.38
Seasonality move
:
-16.61%
Day range:
$3.29 - $3.50
52-week range:
$1.35 - $6.37
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.74x
Volume:
114.7K
Avg. volume:
6.1M
1-year change:
-13.81%
Market cap:
$41.5M
Revenue:
--
EPS (TTM):
-$3.45
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
QTTB
Q32 Bio, Inc.
|
-- | -- | -100% | -- | $15.00 |
|
AKBA
Akebia Therapeutics, Inc.
|
$56.2M | $0.02 | 20.82% | -95.21% | $5.40 |
|
BLTE
Belite Bio, Inc.
|
-- | -$0.51 | -- | -58.83% | $184.33 |
|
CVM
CEL-SCI Corp.
|
-- | -- | -- | -- | $42.50 |
|
IVF
INVO Fertility, Inc.
|
$1.9M | -- | -8.8% | -- | -- |
|
KALA
Kala Bio, Inc.
|
-- | -$1.10 | -- | -43.13% | $1.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
QTTB
Q32 Bio, Inc.
|
$3.37 | $15.00 | $41.5M | -- | $0.00 | 0% | -- |
|
AKBA
Akebia Therapeutics, Inc.
|
$1.51 | $5.40 | $400.7M | -- | $0.00 | 0% | 1.69x |
|
BLTE
Belite Bio, Inc.
|
$159.42 | $184.33 | $6B | -- | $0.00 | 0% | -- |
|
CVM
CEL-SCI Corp.
|
$6.00 | $42.50 | $18.2M | -- | $0.00 | 0% | -- |
|
IVF
INVO Fertility, Inc.
|
$1.01 | -- | $15.3M | -- | $0.00 | 0% | 0.02x |
|
KALA
Kala Bio, Inc.
|
$0.62 | $1.50 | $5.1M | -- | $0.00 | 0% | 7.18x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
QTTB
Q32 Bio, Inc.
|
-1196.42% | 2.670 | 69.88% | 4.41x |
|
AKBA
Akebia Therapeutics, Inc.
|
83.68% | 1.509 | 29.46% | 1.76x |
|
BLTE
Belite Bio, Inc.
|
0.19% | -0.792 | 0.02% | 34.17x |
|
CVM
CEL-SCI Corp.
|
37.03% | 0.660 | 33.61% | 2.14x |
|
IVF
INVO Fertility, Inc.
|
41.99% | 0.410 | 10.12% | 0.07x |
|
KALA
Kala Bio, Inc.
|
140.72% | 2.141 | 263.3% | 0.65x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
QTTB
Q32 Bio, Inc.
|
-$91K | -$7.6M | -256.32% | -634.27% | -- | -$4.2M |
|
AKBA
Akebia Therapeutics, Inc.
|
$49.1M | $4.4M | -7.86% | -- | 7.57% | $28M |
|
BLTE
Belite Bio, Inc.
|
-$347K | -$23M | -37.09% | -37.13% | -- | -- |
|
CVM
CEL-SCI Corp.
|
-$960.8K | -$6M | -117.93% | -230.36% | -- | -$4.7M |
|
IVF
INVO Fertility, Inc.
|
$492.6K | -$1.6M | -188.23% | -471.28% | -93.08% | -$1.8M |
|
KALA
Kala Bio, Inc.
|
-$128K | -$10.7M | -102.67% | -1375.54% | -- | -$10.9M |
Q32 Bio, Inc. vs. Competitors
-
Which has Higher Returns QTTB or AKBA?
Akebia Therapeutics, Inc. has a net margin of -- compared to Q32 Bio, Inc.'s net margin of 0.92%. Q32 Bio, Inc.'s return on equity of -634.27% beat Akebia Therapeutics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital QTTBQ32 Bio, Inc.-- -$0.60 -$1.4M AKBAAkebia Therapeutics, Inc.83.49% $0.00 $254.9M -
What do Analysts Say About QTTB or AKBA?
Q32 Bio, Inc. has a consensus price target of $15.00, signalling upside risk potential of 345.1%. On the other hand Akebia Therapeutics, Inc. has an analysts' consensus of $5.40 which suggests that it could grow by 257.62%. Given that Q32 Bio, Inc. has higher upside potential than Akebia Therapeutics, Inc., analysts believe Q32 Bio, Inc. is more attractive than Akebia Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings QTTBQ32 Bio, Inc.1 1 0 AKBAAkebia Therapeutics, Inc.4 0 0 -
Is QTTB or AKBA More Risky?
Q32 Bio, Inc. has a beta of 0.134, which suggesting that the stock is 86.587% less volatile than S&P 500. In comparison Akebia Therapeutics, Inc. has a beta of 0.354, suggesting its less volatile than the S&P 500 by 64.559%.
-
Which is a Better Dividend Stock QTTB or AKBA?
Q32 Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akebia Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Q32 Bio, Inc. pays -- of its earnings as a dividend. Akebia Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QTTB or AKBA?
Q32 Bio, Inc. quarterly revenues are --, which are smaller than Akebia Therapeutics, Inc. quarterly revenues of $58.8M. Q32 Bio, Inc.'s net income of -$7.4M is lower than Akebia Therapeutics, Inc.'s net income of $540K. Notably, Q32 Bio, Inc.'s price-to-earnings ratio is -- while Akebia Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Q32 Bio, Inc. is -- versus 1.69x for Akebia Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QTTBQ32 Bio, Inc.-- -- -- -$7.4M AKBAAkebia Therapeutics, Inc.1.69x -- $58.8M $540K
-
Which has Higher Returns QTTB or BLTE?
Belite Bio, Inc. has a net margin of -- compared to Q32 Bio, Inc.'s net margin of --. Q32 Bio, Inc.'s return on equity of -634.27% beat Belite Bio, Inc.'s return on equity of -37.13%.
Company Gross Margin Earnings Per Share Invested Capital QTTBQ32 Bio, Inc.-- -$0.60 -$1.4M BLTEBelite Bio, Inc.-- -$0.65 $274.6M -
What do Analysts Say About QTTB or BLTE?
Q32 Bio, Inc. has a consensus price target of $15.00, signalling upside risk potential of 345.1%. On the other hand Belite Bio, Inc. has an analysts' consensus of $184.33 which suggests that it could grow by 15.63%. Given that Q32 Bio, Inc. has higher upside potential than Belite Bio, Inc., analysts believe Q32 Bio, Inc. is more attractive than Belite Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings QTTBQ32 Bio, Inc.1 1 0 BLTEBelite Bio, Inc.5 0 0 -
Is QTTB or BLTE More Risky?
Q32 Bio, Inc. has a beta of 0.134, which suggesting that the stock is 86.587% less volatile than S&P 500. In comparison Belite Bio, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock QTTB or BLTE?
Q32 Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Belite Bio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Q32 Bio, Inc. pays -- of its earnings as a dividend. Belite Bio, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QTTB or BLTE?
Q32 Bio, Inc. quarterly revenues are --, which are smaller than Belite Bio, Inc. quarterly revenues of --. Q32 Bio, Inc.'s net income of -$7.4M is higher than Belite Bio, Inc.'s net income of -$21.7M. Notably, Q32 Bio, Inc.'s price-to-earnings ratio is -- while Belite Bio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Q32 Bio, Inc. is -- versus -- for Belite Bio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QTTBQ32 Bio, Inc.-- -- -- -$7.4M BLTEBelite Bio, Inc.-- -- -- -$21.7M
-
Which has Higher Returns QTTB or CVM?
CEL-SCI Corp. has a net margin of -- compared to Q32 Bio, Inc.'s net margin of --. Q32 Bio, Inc.'s return on equity of -634.27% beat CEL-SCI Corp.'s return on equity of -230.36%.
Company Gross Margin Earnings Per Share Invested Capital QTTBQ32 Bio, Inc.-- -$0.60 -$1.4M CVMCEL-SCI Corp.-- -$0.76 $25.3M -
What do Analysts Say About QTTB or CVM?
Q32 Bio, Inc. has a consensus price target of $15.00, signalling upside risk potential of 345.1%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 608.33%. Given that CEL-SCI Corp. has higher upside potential than Q32 Bio, Inc., analysts believe CEL-SCI Corp. is more attractive than Q32 Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings QTTBQ32 Bio, Inc.1 1 0 CVMCEL-SCI Corp.1 0 0 -
Is QTTB or CVM More Risky?
Q32 Bio, Inc. has a beta of 0.134, which suggesting that the stock is 86.587% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.538, suggesting its less volatile than the S&P 500 by 46.183%.
-
Which is a Better Dividend Stock QTTB or CVM?
Q32 Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Q32 Bio, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QTTB or CVM?
Q32 Bio, Inc. quarterly revenues are --, which are smaller than CEL-SCI Corp. quarterly revenues of --. Q32 Bio, Inc.'s net income of -$7.4M is lower than CEL-SCI Corp.'s net income of -$6.1M. Notably, Q32 Bio, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Q32 Bio, Inc. is -- versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QTTBQ32 Bio, Inc.-- -- -- -$7.4M CVMCEL-SCI Corp.-- -- -- -$6.1M
-
Which has Higher Returns QTTB or IVF?
INVO Fertility, Inc. has a net margin of -- compared to Q32 Bio, Inc.'s net margin of -150.51%. Q32 Bio, Inc.'s return on equity of -634.27% beat INVO Fertility, Inc.'s return on equity of -471.28%.
Company Gross Margin Earnings Per Share Invested Capital QTTBQ32 Bio, Inc.-- -$0.60 -$1.4M IVFINVO Fertility, Inc.28.04% -$6.14 $10.1M -
What do Analysts Say About QTTB or IVF?
Q32 Bio, Inc. has a consensus price target of $15.00, signalling upside risk potential of 345.1%. On the other hand INVO Fertility, Inc. has an analysts' consensus of -- which suggests that it could grow by 14157.43%. Given that INVO Fertility, Inc. has higher upside potential than Q32 Bio, Inc., analysts believe INVO Fertility, Inc. is more attractive than Q32 Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings QTTBQ32 Bio, Inc.1 1 0 IVFINVO Fertility, Inc.0 0 0 -
Is QTTB or IVF More Risky?
Q32 Bio, Inc. has a beta of 0.134, which suggesting that the stock is 86.587% less volatile than S&P 500. In comparison INVO Fertility, Inc. has a beta of 2.606, suggesting its more volatile than the S&P 500 by 160.551%.
-
Which is a Better Dividend Stock QTTB or IVF?
Q32 Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. INVO Fertility, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Q32 Bio, Inc. pays -- of its earnings as a dividend. INVO Fertility, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QTTB or IVF?
Q32 Bio, Inc. quarterly revenues are --, which are smaller than INVO Fertility, Inc. quarterly revenues of $1.8M. Q32 Bio, Inc.'s net income of -$7.4M is lower than INVO Fertility, Inc.'s net income of -$2.6M. Notably, Q32 Bio, Inc.'s price-to-earnings ratio is -- while INVO Fertility, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Q32 Bio, Inc. is -- versus 0.02x for INVO Fertility, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QTTBQ32 Bio, Inc.-- -- -- -$7.4M IVFINVO Fertility, Inc.0.02x -- $1.8M -$2.6M
-
Which has Higher Returns QTTB or KALA?
Kala Bio, Inc. has a net margin of -- compared to Q32 Bio, Inc.'s net margin of --. Q32 Bio, Inc.'s return on equity of -634.27% beat Kala Bio, Inc.'s return on equity of -1375.54%.
Company Gross Margin Earnings Per Share Invested Capital QTTBQ32 Bio, Inc.-- -$0.60 -$1.4M KALAKala Bio, Inc.-- -$1.07 $21.3M -
What do Analysts Say About QTTB or KALA?
Q32 Bio, Inc. has a consensus price target of $15.00, signalling upside risk potential of 345.1%. On the other hand Kala Bio, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 143.51%. Given that Q32 Bio, Inc. has higher upside potential than Kala Bio, Inc., analysts believe Q32 Bio, Inc. is more attractive than Kala Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings QTTBQ32 Bio, Inc.1 1 0 KALAKala Bio, Inc.0 2 0 -
Is QTTB or KALA More Risky?
Q32 Bio, Inc. has a beta of 0.134, which suggesting that the stock is 86.587% less volatile than S&P 500. In comparison Kala Bio, Inc. has a beta of -2.429, suggesting its less volatile than the S&P 500 by 342.929%.
-
Which is a Better Dividend Stock QTTB or KALA?
Q32 Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kala Bio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Q32 Bio, Inc. pays -- of its earnings as a dividend. Kala Bio, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QTTB or KALA?
Q32 Bio, Inc. quarterly revenues are --, which are smaller than Kala Bio, Inc. quarterly revenues of --. Q32 Bio, Inc.'s net income of -$7.4M is higher than Kala Bio, Inc.'s net income of -$7.6M. Notably, Q32 Bio, Inc.'s price-to-earnings ratio is -- while Kala Bio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Q32 Bio, Inc. is -- versus 7.18x for Kala Bio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QTTBQ32 Bio, Inc.-- -- -- -$7.4M KALAKala Bio, Inc.7.18x -- -- -$7.6M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 36x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
64
RGC alert for Jan 6
Regencell Bioscience Holdings Ltd. [RGC] is up 22.74% over the past day.
Buy
73
INOD alert for Jan 6
Innodata, Inc. [INOD] is up 4.84% over the past day.
Buy
65
AVAV alert for Jan 6
AeroVironment, Inc. [AVAV] is up 6.62% over the past day.
